Effect of Acetyl-L-carnitine on Chronic Pancreatitis

Stopped early · Early Phase 1

Conditions studied: Chronic Pancreatitis

In brief

An open label pilot study will determine the effect of the amino acid nutritional supplement acetyl-L-carnitine (ALC) on pain, quality of life, well-being, and serum pro-inflammatory mediator and oxidative stress levels in volunteers with chronic pancreatitis. The ALC is given to all participants for 3 months, and assessments will occur at intake and after 3 months.

Key facts

Study ID

NCT02538146

Run by

Karin High

People needed

3

Starts

2015-08-01

Expected to finish

2016-10-01

Last updated by the study team

2017-03-10

Who can join

Age: 20 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Only patients with chronic pancreatitis are included.

You may not qualify if…

• Patients with pancreatic pseudocysts, abscesses, pseudoaneurysms, pancreatitic fistulas, pancreatic adenocarcinoma,
• Females that are pregnant or lactating
• Children are excluded.
• Patients suffering from seizure or thyroid disorders are also excluded due to possible exaggeration of their symptoms from taking ALC according to manufacturer.

Where it is running

• University of Kentucky Center for Clinical and Translational Science — Lexington, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.